STOCK TITAN

Appili Therapeutics Inc - APLIF STOCK NEWS

Welcome to our dedicated news page for Appili Therapeutics (Ticker: APLIF), a resource for investors and traders seeking the latest updates and insights on Appili Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Appili Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Appili Therapeutics's position in the market.

Rhea-AI Summary
Aditxt, Inc. (NASDAQ: ADTX) has entered into an agreement to acquire Appili Therapeutics Inc., a biopharmaceutical company focused on infectious diseases. Appili's assets include the FDA-approved LIKMEZ™, ATI-1701 tularemia vaccine defense program, and ATI-1801 topical formulation. The acquisition aims to enhance Aditxt's portfolio and create synergies in precision diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.97%
Tags
-
Rhea-AI Summary
Appili Therapeutics Inc. announces a publication in the journal Frontiers in Bacteriology on the prevention of tularemia in Ukraine, highlighting the potential role of ATI-1701 in biodefense. The company collaborates with Ukrainian and U.S. researchers to assess the risk of tularemia outbreaks in Ukraine, emphasizing the urgent need for protection against infectious diseases. ATI-1701, a first-in-class vaccine candidate, aims to address the lack of approved tularemia vaccines in major global markets, positioning itself as a crucial biodefense solution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Appili Therapeutics Inc. (APLI) announced that the USPTO has granted a patent for ATI-1701, a biodefense vaccine candidate, providing market exclusivity through 2039. The company also received a pre-IND meeting with the FDA and amended the terms of a bridge loan with Bloom Burton.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Appili Therapeutics Inc. (APLI) announces FDA approval for ATI-1501, branded as LIKMEZ, for the treatment of anaerobic bacterial infections. The company also secured an additional funding commitment of US$14 million from the U.S. Air Force Academy for ATI-1701. Prakash Gowd has been appointed to the Board of Directors. The company reported a net loss and comprehensive loss of $1.0 million for the three months ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.29%
Tags
-
Rhea-AI Summary
Appili Therapeutics secures additional $6.6 million funding for ATI-1701 vaccine program. Total program funding now at $14 million. Change in Board of Directors announced.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.79%
Tags
none
-
Rhea-AI Summary
Appili Therapeutics announces positive results from annual meeting of shareholders and recent progress in drug development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.33%
Tags
none
Rhea-AI Summary
Appili Therapeutics announces funding commitment from U.S. Air Force for biodefense vaccine candidate ATI-1701
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.79%
Tags
none
-
Rhea-AI Summary
FDA approves LIKMEZ as brand name for Metronidazole Oral Suspension, providing market exclusivity through 2039
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.5%
Tags
-
Rhea-AI Summary
Appili Therapeutics Inc. announces Q1 2024 financial and operational results. They secured $7.3 million in funding for their ATI-1701 vaccine from the Defense Threat Reduction Agency and USAFA. They also obtained a US patent for their Metronidazole formulation. FDA established a PDUFA action date for ATI-1501 on September 23, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
none
Appili Therapeutics Inc

Nasdaq:APLIF

APLIF Rankings

APLIF Stock Data

3.52M
106.83M
0.06%
11.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Halifax